Lunai Bioworks (2Q5) Stock Statistics & Valuation Metrics
Total Valuation
Lunai Bioworks has a market cap or net worth of EUR 741.82K. The enterprise value is EUR 16.39T.
- Market Cap
- EUR 741.82K
- Enterprise Value
- EUR 16.39T
Share Statistics
Lunai Bioworks has 5,034,452 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 5,034,452
- Owned by Insiders
- ―
- Owned by Institutions
- 3.41%
Financial Efficiency
Lunai Bioworks’s return on equity (ROE) is 0.39 and return on invested capital (ROIC) is 102.33%.
- Return on Equity (ROE)
- 0.39
- Return on Assets (ROA)
- -0.36
- Return on Invested Capital (ROIC)
- 102.33%
- Return on Capital Employed (ROCE)
- 0.88
- Revenue Per Employee
- 4,332.667
- Profits Per Employee
- -296.87K
- Employee Count
- 12
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Lunai Bioworks is -0.20. Lunai Bioworks’s PEG ratio is -0.00.
- PE Ratio
- -0.20
- PS Ratio
- 15.96
- PB Ratio
- -0.08
- Price to FCF
- -0.16
- Price to Operating Cash Flow
- -0.14
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Lunai Bioworks had revenue of 51.99K and earned -3.56M in profits. Earnings per share was -1.06.
- Revenue
- 51.99K
- Gross Profit
- -41.53K
- Operating Income
- -7.87M
- Pretax Income
- -3.56M
- Net Income
- -3.56M
- EBITDA
- -7.77M
- Earnings Per Share (EPS)
- -1.06
Cash Flow
In the last 12 months, operating cash flow was -5.29M and capital expenditures -4, giving a free cash flow of -5.29M billion.
- Operating Cash Flow
- -5.29M
- Free Cash Flow
- -5.29M
- Free Cash Flow per Share
- -1.15
Dividends & Yields
Lunai Bioworks pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -637.53%
- Earnings Yield
- -468.36%
Stock Price Statistics
- Beta
- 1.47
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 0.82
- 200-Day Moving Average
- 0.82
- Relative Strength Index (RSI)
- 21.53
- Average Volume (3m)
- ―
Financial Position
Lunai Bioworks as a current ratio of 0.11, with Debt / Equity ratio of -14.83%
- Current Ratio
- 0.11
- Quick Ratio
- 0.11
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- 0.05
- Interest Coverage Ratio
- -33.46
Taxes
In the past 12 months, Lunai Bioworks has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Lunai Bioworks EV to EBITDA ratio is 118.11, with an EV/FCF ratio of 70.79.
- EV to Sales
- -7202.13
- EV to EBITDA
- 118.11
- EV to Free Cash Flow
- 70.79
- EV to Operating Cash Flow
- 70.81
Balance Sheet
Lunai Bioworks has EUR 1.71B in cash and marketable securities with EUR 1.34B in debt, giving a net cash position of EUR 375.28M billion.
- Cash & Marketable Securities
- EUR 1.71B
- Total Debt
- EUR 1.34B
- Net Cash
- EUR 375.28M
- Net Cash Per Share
- EUR 74.54
- Tangible Book Value Per Share
- -EUR 3,641.50
Margins
Gross margin is -79.88%, with operating margin of -15129.29%, and net profit margin of -6851.97%.
- Gross Margin
- -79.88%
- Operating Margin
- -15129.29%
- Pretax Margin
- -6851.97%
- Net Profit Margin
- -6851.97%
- EBITDA Margin
- -6097.91%
- EBIT Margin
- -6294.10%
Analyst Forecast
The average price target for Lunai Bioworks is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 99.03%
